<div id="readability-page-1"><div>(TheNewswire)VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the“Company”) is providing this bi-weekly update on the status of themanagement cease trade order granted on March 3, 2026 (the“MCTO”), by its principal regulator, the British ColumbiaSecurities Commission (the “BCSC”) under National Policy 12-203 –Management Cease TradeOrders (“NP 12-203”). The Company announced on March3, 2026 (the “DefaultAnnouncement”), that it was unable to file itsaudited annual financial statements for the year ended October 31,2025, the related management’s discussion and analysis, and its Form52-109FV1 CEO and CFO certifications of annual filings (collectivelythe “AnnualFilings”). Under National Instrument 51-102 -Continuous DisclosureObligations, the Annual Filings were required tobe made not later than February 28, 2026.The Company is actively working with its auditor, DaleMatheson Carr-Hilton LaBonte LLP, to complete the Annual Filings,which will be filed as soon as possible. As previously stated, subjectto current conditions remaining the same, the Company remainsconfident in its ability to complete the Annual Filings by April 28,2026.As a result of this further delay in filing the AnnualFilings, the Company anticipates it will not be in a position to fileits interim financial statements for the three months ended January31, 2025, its management’s discussion and analysis of financialstatements for the three months ended January 31, 2025, and relatedfilings (collectively, the “Interim Filings”). Under National Instrument51-102, the Interim Filings are required to be made not later thanApril 1, 2026. The Company anticipates filing the Interim Filingsimmediately after the filing of the Annual Filings.Except as herein disclosed, there are no materialchanges to the information contained in the Default Announcement. Inaddition, (i) the Company is satisfying and confirms that it intendsto continue to satisfy the provisions of the alternative informationguidelines under NP 12-203 and issue bi-weekly default status reportsin the form of news releases, for so long as the Company remains indefault with the Annual Filings and /or Interim Filings; (ii) theCompany does not have any information at this time regarding anyanticipated specified default subsequent to the default in filing theAnnual Filings; (iii) the Company confirms that, as of the date ofthis news release, that the Company is not subject to any insolvencyproceedings; and (iv) there is no other material informationconcerning the affairs of the Company that has not been generallydisclosed.The Company confirms that while the MCTO is in effect,the general investing public will continue to be able to trade freelythe Company’s listed common shares. However, the MCTO prohibits theCompany’s Chief Executive Officer and Chief Financial Officer fromtrading securities of the Company for so long as the Annual Filingsare not filed. Additionally, the Company will be prohibited fromdirectly or indirectly issuing or acquiring securities from insidersor employees of the Company until such time as the Annual Filings havebeen made and all continuous disclosure requirements have been met bythe Company, and the MCTO has been revoked.About BioVaxys TechnologyCorp.BioVaxys Technology Corp. (www.biovaxys.com), abiopharmaceuticals company registered in British Columbia, Canada, isa clinical-stage biopharmaceutical company dedicated to improvingpatient lives with novel immunotherapies based on the DPX™immune-educating technology platform and it’s HapTenix© tumor cellconstruct platform, for treating cancers, infectious disease, antigendesensitization for food allergy, and other immunological diseases.Through a differentiated mechanism of action, the DPX™ platformdelivers instruction to the immune system to generate a specific,robust, and persistent immune response. The Company's clinicalstage pipeline includes maveropepimut-S (MVP-S), based on the DPX™platform, in phase IIB clinical development for advancedRelapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinumresistant Ovarian Cancer. MVP-S delivers antigenic peptides from thesurvivin family, a set of well-recognized cancer antigens commonlyoverexpressed in advanced cancers, and also delivers an innate immuneactivator and a universal CD4 T cell helper peptide. MVP-S has beenwell tolerated and has demonstrated defined clinical benefit inmultiple cancer indications as well as the activation of a targetedand sustained, survivin-specific anti-tumor immune response. BioVaxysis also developing DPX™+SurMAGE, a dual-targeted immunotherapycombining antigenic peptides for both the survivin and MAGE-A9 cancerproteins to elicit immune responses to these two distinct cancerantigens simultaneously, MVP-S+letrozole for Stage II-III HR+/HER2-breast cancer, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA forpeanut allergy prophylaxis, and BVX-0918, a personalizedimmunotherapeutic vaccine using its proprietary HapTenix©'neoantigen' tumor cell construct platform for refractivelate-stage ovarian cancer.BioVaxys common shares are listed on the CSE under thestock symbol “BIOV” and trade on the Frankfurt Bourse (FSE: 5LB0) and in the U.S. on the OTC Markets (OTCQB: BVAXF). For moreinformation, visit www.biovaxys.com and connect with us on X andLinkedIn.ON BEHALF OF THE BOARDSigned “James Passin”James Passin, Chief Executive OfficerPhone: +1 740 358 0555Cautionary Statements RegardingForward Looking InformationThis press release includes certain&#34;forward-looking information&#34; and &#34;forward-lookingstatements&#34; (collectively &#34;forward-looking statements&#34;) within the meaning of applicable securities legislation. Allstatements, other than statements of historical fact, included herein,without limitation, statements relating to the filings of the AnnualFilings by April 28, 2026, the Company’s ability to comply with theprovision of the alternative information guidelines described by NP12-203, and future operating or financial performance of the Company,are forward-looking statements. Forward-looking statements arefrequently, but not always, identified by words such as&#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;,&#34;intends&#34;, &#34;estimates&#34;, &#34;potential&#34;,&#34;possible&#34;, and similar expressions, or statements thatevents, conditions, or results &#34;will&#34;, &#34;may&#34;,&#34;could&#34;, or &#34;should&#34; occur or be achieved. Therecan be no assurance that such statements will prove to be accurate,and actual results and future events could differ materially fromthose expressed or implied in such forward-looking statements.These forward-looking statementsreflect the beliefs, opinions and projections on the date thestatements are made and are based upon a number of assumptions andestimates, primarily the assumptions that the Company and its auditorwill be able to complete the Annual Filings and that BioVaxys will besuccessful in developing and testing vaccines, that, while consideredreasonable by the Company, are inherently subject to significantbusiness, economic, competitive, political and social uncertaintiesand contingencies including, primarily but without limitation, therisk that BioVaxys' vaccines will not prove to be effective and/or will not receive the required regulatory approvals. With regards toBioVaxys' business, there are a number of risks that could affectthe development of its biotechnology products, including, withoutlimitation, the need for additional capital to fund clinical trials,its lack of operating history, uncertainty about whether its productswill complete the long, complex and expensive clinical trial andregulatory approval process for approval of new drugs necessary formarketing approval, uncertainty about whether its autologous cellvaccine immunotherapy can be developed to produce safe and effectiveproducts and, if so, whether its vaccine products will be commerciallyaccepted and profitable, the expenses, delays and uncertainties andcomplications typically encountered by development stagebiopharmaceutical businesses, financial and development obligationsunder license arrangements in order to protect its rights to itsproducts and technologies, obtaining and protecting new intellectualproperty rights and avoiding infringement to third parties and theirdependence on manufacturing by third parties.The Company does not assume anyobligation to update the forward-looking statements of beliefs,opinions, projections, or other factors, should they change, except asrequired by law. Investors are encouraged to read BioVaxys continuousdisclosure documents and audited annual consolidated financialstatements which are available on SEDAR+ at www.sedarplus.ca. The Canadian Securities Exchange has notreviewed, approved nor disapproved the contents of this press releaseand does not accept responsibility for the adequacy or accuracy ofthis release.Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

SBIO

DVAX

ARKG

BioVaxys Technology Corp. has provided a bi-weekly update regarding its management cease trade order (MCTO) issued by the British Columbia Securities Commission. The company is working to complete its audited annual financial statements, which were due by February 28, 2026, and anticipates filing them by April 28, 2026. Due to this delay, the company will also postpone its interim financial statements due by April 1, 2026. The MCTO restricts trading for the CEO and CFO but allows public trading of the company's shares.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update